Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil.
A case of palmar-plantar erythrodysesthesia syndrome (PPES) observed during a 120-h infusion of 5-fluorouracil (5-FU) is presented. This syndrome has been described in the literature after protracted infusion chemotherapy of over 30 days. The agent most frequently associated with this syndrome was 5-FU. A 53-year-old man was admitted to the hospital with a well-differentiated squamous cell carcinoma of the retromolar trigone. The patient received 100 mg/m2 of cisplatin on day 1 and 120-h continuous infusion of 1000 mg/m2 of 5-FU every 3 weeks. After the second course, the patient developed clinical features consistent with PPES. This side effect has not been previously reported with short-term (5-day or 120-h) continuous infusion of 5-FU. Less frequently, the syndrome has also been described with 10-day continuous infusion. The etiopathogenesis of PPES is unclear, but it seems to be dose-dependent and probably related to cutaneous drug accumulation.
Bellmunt
J
J
Department of Radiotherapy and Oncology, Valle Hebron Hospital, Barcelona, Spain.
Navarro
M
M
Hidalgo
R
R
Solé
L A
LA
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004890:Erythema / Q000139:chemically induced*; D005472:Fluorouracil / Q000009:adverse effects* / Q000627:therapeutic use; D005528:Foot; D006225:Hand; D006801:Humans; D008297:Male; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced*; D013577:Syndrome; D013997:Time Factors
D005472:Fluorouracil